We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

63 hedge funds and large institutions have $168M invested in Cue Biopharma in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 6

227% more capital invested

Capital invested by funds: $51.3M → $168M (+$116M)

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

40% more funds holding

Funds holding: 45 → 63 (+18)

0.63% more ownership

Funds ownership: 0.9% → 1.53% (+0.63%)

Holders
63
Holders Change
+18
Holders Change %
+40%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
22
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$19.6M
2
MP
Mangrove Partners
Connecticut
+$6.3M
3
CAG
Crestwood Advisors Group
Massachusetts
+$2.83M
4
PM
Precept Management
Texas
+$1.78M
5
BlackRock
BlackRock
New York
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$422K
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$397K
3
Millennium Management
Millennium Management
New York
-$117K
4
Citigroup
Citigroup
New York
-$108K
5
PGM
Parian Global Management
New York
-$93K
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
51
Metropolitan Life Insurance Company (MetLife)
New York
$114K +$75.1K +239 New
JP Morgan Chase
52
JP Morgan Chase
New York
$108K +$4.08K +13 +6%
Legal & General Group
53
Legal & General Group
United Kingdom
$68K +$7.54K +24 +20%
Citigroup
54
Citigroup
New York
$65K -$108K -343 -72%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$49K +$7.85K +25 +32%
BNP Paribas Financial Markets
56
BNP Paribas Financial Markets
France
$41.3K -$3.46K -11 -11%
DOA
57
D'Orazio & Associates
Virginia
$32K – – –
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$26K +$17.3K +55 New
AIP
59
Ameritas Investment Partners
Nebraska
$25K – – –
LTFS
60
Ladenburg Thalmann Financial Services
Florida
$2K – – –
PNC Financial Services Group
61
PNC Financial Services Group
Pennsylvania
$2K – – –
Marshall Wace
62
Marshall Wace
United Kingdom
$2K +$942 +3 New
SFM
63
Sphera Funds Management
Israel
– -$422K -1,667 Closed
Millennium Management
64
Millennium Management
New York
– -$117K -464 Closed
PGM
65
Parian Global Management
New York
– -$93K -367 Closed
PPA
66
Parametric Portfolio Associates
Washington
– -$85K -336 Closed
Victory Capital Management
67
Victory Capital Management
Texas
– -$29K -116 Closed
MAM
68
Meeder Asset Management
Ohio
– -$5.97K -19 -95%
TRCT
69
Tower Research Capital (TRC)
New York
– -$4K -17 Closed
1 2
3

CUE Hedge Fund Activity: Q4 2019 in Review

63 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2019, worth a combined $168M — up 227% from $51.3M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CUE positions and 6 closed out — a net gain of 18 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $19.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $422K sold.

  • 63 institutional investors held Cue Biopharma (CUE) as of Q4 2019, up from 45 in Q3 2019.
  • Funds reported $168M of Cue Biopharma stock for Q4 2019, up 227% quarter-over-quarter.
  • 24 funds opened new Cue Biopharma positions in Q4 2019 and 6 closed out, a net change of +18 holders.
  • The largest Cue Biopharma buyer in Q4 2019 was Avoro Capital Advisors, an estimated $19.6M added.
  • The largest Cue Biopharma seller in Q4 2019 was Sphera Funds Management, an estimated $422K sold.

Based on aggregated 13F filings for Q4 2019.